Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients

Background: The Memorial Sloan–Kettering Cancer Center (MSKCC) prognostic model has been widely used for the prediction of the outcome of metastatic renal cell carcinoma (mRCC) patients treated with systemic therapies, however, data from large studies are limited. This study aimed at the evaluation...

Descripción completa

Detalles Bibliográficos
Autores principales: Fiala, Ondrej, Finek, Jindrich, Poprach, Alexandr, Melichar, Bohuslav, Kopecký, Jindrich, Zemanova, Milada, Kopeckova, Katerina, Mlcoch, Tomas, Dolezal, Tomas, Capkova, Lenka, Buchler, Tomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225945/
https://www.ncbi.nlm.nih.gov/pubmed/32230921
http://dx.doi.org/10.3390/cancers12040808

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225945/
https://www.ncbi.nlm.nih.gov/pubmed/32230921
http://dx.doi.org/10.3390/cancers12040808

Ejemplares similares